CA2577407A1 - Methode de diagnostic genetique destinee a la stratification du risque scd - Google Patents
Methode de diagnostic genetique destinee a la stratification du risque scd Download PDFInfo
- Publication number
- CA2577407A1 CA2577407A1 CA002577407A CA2577407A CA2577407A1 CA 2577407 A1 CA2577407 A1 CA 2577407A1 CA 002577407 A CA002577407 A CA 002577407A CA 2577407 A CA2577407 A CA 2577407A CA 2577407 A1 CA2577407 A1 CA 2577407A1
- Authority
- CA
- Canada
- Prior art keywords
- scd
- snp
- group
- seq
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000013517 stratification Methods 0.000 title description 14
- 230000002068 genetic effect Effects 0.000 title description 9
- 238000002405 diagnostic procedure Methods 0.000 title description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000002773 nucleotide Substances 0.000 claims abstract description 18
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 18
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 102200108502 rs7626962 Human genes 0.000 claims description 12
- 102200132858 rs6964587 Human genes 0.000 claims description 9
- 230000036982 action potential Effects 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 7
- 230000000747 cardiac effect Effects 0.000 claims description 7
- 102100033063 G protein-activated inward rectifier potassium channel 1 Human genes 0.000 claims description 3
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 claims description 3
- 101001135471 Homo sapiens Potassium voltage-gated channel subfamily D member 3 Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 102100033184 Potassium voltage-gated channel subfamily D member 3 Human genes 0.000 claims description 3
- 102100039290 Gap junction gamma-1 protein Human genes 0.000 claims description 2
- 101000746078 Homo sapiens Gap junction gamma-1 protein Proteins 0.000 claims description 2
- 101001026209 Homo sapiens Potassium voltage-gated channel subfamily A member 4 Proteins 0.000 claims description 2
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 claims description 2
- 101001032038 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Proteins 0.000 claims description 2
- 102100037449 Potassium voltage-gated channel subfamily A member 4 Human genes 0.000 claims description 2
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 claims description 2
- 102100027391 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Human genes 0.000 claims description 2
- 102000004912 RYR2 Human genes 0.000 claims description 2
- 108060007241 RYR2 Proteins 0.000 claims description 2
- 102100035088 Sodium/calcium exchanger 1 Human genes 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 238000004422 calculation algorithm Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 102000014814 CACNA1C Human genes 0.000 claims 1
- 102000014837 CACNA1G Human genes 0.000 claims 1
- 102000014835 CACNA1H Human genes 0.000 claims 1
- 102000014836 CACNA1I Human genes 0.000 claims 1
- 101001049831 Homo sapiens Potassium channel subfamily K member 4 Proteins 0.000 claims 1
- 101001026214 Homo sapiens Potassium voltage-gated channel subfamily A member 5 Proteins 0.000 claims 1
- 101001135486 Homo sapiens Potassium voltage-gated channel subfamily D member 2 Proteins 0.000 claims 1
- 101001009079 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Proteins 0.000 claims 1
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims 1
- 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 claims 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 claims 1
- 101000932785 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1I Proteins 0.000 claims 1
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 claims 1
- 102100023205 Potassium channel subfamily K member 4 Human genes 0.000 claims 1
- 102100037445 Potassium voltage-gated channel subfamily A member 5 Human genes 0.000 claims 1
- 102100033170 Potassium voltage-gated channel subfamily D member 2 Human genes 0.000 claims 1
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 claims 1
- 102100038718 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Human genes 0.000 claims 1
- -1 SCNA5 Proteins 0.000 claims 1
- 108091006253 SLC8A1 Proteins 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 71
- 108700028369 Alleles Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 28
- 230000006870 function Effects 0.000 description 25
- 230000015556 catabolic process Effects 0.000 description 23
- 206010003119 arrhythmia Diseases 0.000 description 19
- 230000006793 arrhythmia Effects 0.000 description 19
- 241000282326 Felis catus Species 0.000 description 15
- 238000003359 percent control normalization Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000000546 chi-square test Methods 0.000 description 5
- 208000021005 inheritance pattern Diseases 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 230000004057 allelic distribution Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010047302 ventricular tachycardia Diseases 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002001 electrophysiology Methods 0.000 description 3
- 230000007831 electrophysiology Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- 102100040084 A-kinase anchor protein 9 Human genes 0.000 description 2
- 101150082664 AKAP9 gene Proteins 0.000 description 2
- 101100465060 Arabidopsis thaliana PRK4 gene Proteins 0.000 description 2
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 2
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 2
- 101100324788 Caenorhabditis elegans atg-5 gene Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 101000890598 Homo sapiens A-kinase anchor protein 9 Proteins 0.000 description 2
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 2
- 108010048829 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101150012075 Kcnj3 gene Proteins 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 101150042605 RYR2 gene Proteins 0.000 description 2
- 101150069400 Slc8a1 gene Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 102000006889 calcium:sodium antiporter activity proteins Human genes 0.000 description 2
- 108040000797 calcium:sodium antiporter activity proteins Proteins 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000010220 ion permeability Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 101150078635 18 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000007195 Andersen Syndrome Diseases 0.000 description 1
- 201000006060 Andersen-Tawil syndrome Diseases 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 101100059607 Caenorhabditis elegans cec-3 gene Proteins 0.000 description 1
- 101100480622 Caenorhabditis elegans tat-5 gene Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
- 101710178004 Gap junction gamma-1 protein Proteins 0.000 description 1
- 101150102932 HCN1 gene Proteins 0.000 description 1
- 101150038687 HCN2 gene Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101001023149 Homo sapiens Sodium/calcium exchanger 1 Proteins 0.000 description 1
- 102000009453 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 101150031045 KCNA5 gene Proteins 0.000 description 1
- 101150038292 KCND2 gene Proteins 0.000 description 1
- 101150098715 KCND3 gene Proteins 0.000 description 1
- 101150115742 Kcna4 gene Proteins 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 1
- 244000166071 Shorea robusta Species 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 102000038652 low voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091092917 low voltage-gated calcium channel activity Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000000661 pacemaking effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 230000007384 vagal nerve stimulation Effects 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USUNKNOWN | 2002-10-17 | ||
| US58235204P | 2004-06-23 | 2004-06-23 | |
| US60/582,352 | 2004-06-23 | ||
| US58990704P | 2004-07-21 | 2004-07-21 | |
| US60/589,907 | 2004-07-21 | ||
| PCT/US2005/022033 WO2006012134A2 (fr) | 2004-06-23 | 2005-06-22 | Methode de diagnostic genetique destinee a la stratification du risque scd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2577407A1 true CA2577407A1 (fr) | 2006-02-02 |
Family
ID=37951627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002577407A Abandoned CA2577407A1 (fr) | 2004-06-23 | 2005-06-22 | Methode de diagnostic genetique destinee a la stratification du risque scd |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2577407A1 (fr) |
-
2005
- 2005-06-22 CA CA002577407A patent/CA2577407A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andersen et al. | Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives | |
| US8027791B2 (en) | Self-improving classification system | |
| US20090131276A1 (en) | Diagnostic kits and methods for scd or sca therapy selection | |
| US8335652B2 (en) | Self-improving identification method | |
| CN104736723B (zh) | 用于预测对fgf‑18化合物的响应性的遗传标记 | |
| US11312994B2 (en) | Methods and compositions for SCD, CRT, CRT-D, or SCA therapy identification and/or selection | |
| MX2013008846A (es) | Metodo para descubrir biomarcadores farmacogenomicos. | |
| US20050287574A1 (en) | Genetic diagnostic method for SCD risk stratification | |
| US20100317006A1 (en) | Sca risk stratification by predicting patient response to anti-arrhythmics | |
| CN104755629A (zh) | 软骨疾病的预后生物标记 | |
| US20070031853A1 (en) | Gene sequence variations with utility in determining the treatment of neurological or psychiatric disease | |
| US20010049586A1 (en) | Iterative analysis of non-responding population in the design of pharmacogenetic studies | |
| US20110143956A1 (en) | Diagnostic Kits and Methods for SCD or SCA Therapy Selection | |
| CA2577407A1 (fr) | Methode de diagnostic genetique destinee a la stratification du risque scd | |
| US20150211066A1 (en) | Methods and Compositions for Correlating Genetic Markers with Sudden Cardiac Death Risk | |
| US20120309641A1 (en) | Diagnostic kits, genetic markers, and methods for scd or sca therapy selection | |
| EP2463384A2 (fr) | Kits de diagnostic, marqueurs génétiques et procédés pour la sélection d'un traitement SCD ou SCA | |
| US20110143345A1 (en) | Genetic Markers for SCD or SCA Therapy Selection | |
| Foddha et al. | Comparing the SCN5A Gene Sequence and Expression in Three Different Brugada Syndrome Profiles of Patients: New Insights for Genotype-Phenotype Correlation | |
| KR20110043100A (ko) | Ａｎｋｒｄ15, ｈｐｄ, ｐｓｍｄ9, ｗｄｒ66, ｇｐｃ6, ｐａｘ9, ｌｒｒｃ28, ｔｎｓ4, ａｘｌ, 및 ｈｎｒｐｕｌ1 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법 | |
| Spijker et al. | Allelic association study on 11 candidate genes potentially relevant for the development of microalbuminuria | |
| Acrocentric et al. | Terms and Phrases | |
| HK1207401B (en) | Genetic markers for predicting responsiveness to fgf-18 compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |